07:01 AM EDT, 06/20/2025 (MT Newswires) -- Evolent Health ( EVH ) reiterated Friday its Q2 adjusted EBITDA guidance of $33 million to $40 million.

Analysts polled by FactSet expect $35.3 million.

The company also continues to expect full-year adjusted EBITDA of $135 million to $165 million. Analysts surveyed by FactSet expect $151 million.

Evolent further said it signed a commitment letter with Ares Management Credit funds to borrow additional non-dilutive capital, if needed, to redeem its 2025 convertible notes.